|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0009450,
umls-concept:C0010583,
umls-concept:C0030705,
umls-concept:C0059985,
umls-concept:C0205087,
umls-concept:C0234227,
umls-concept:C0393022,
umls-concept:C0686907,
umls-concept:C1518071,
umls-concept:C1550587
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-5-30
|
|
pubmed:abstractText |
Whether the addition of rituximab to fludarabine and cyclosphosphamide (FC) increases early or late infection risk remains poorly defined. This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
700-2
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15921393-Adult,
pubmed-meshheading:15921393-Aged,
pubmed-meshheading:15921393-Aged, 80 and over,
pubmed-meshheading:15921393-Antibodies, Monoclonal,
pubmed-meshheading:15921393-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15921393-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15921393-Cohort Studies,
pubmed-meshheading:15921393-Cyclophosphamide,
pubmed-meshheading:15921393-Disease Susceptibility,
pubmed-meshheading:15921393-Female,
pubmed-meshheading:15921393-Herpesviridae Infections,
pubmed-meshheading:15921393-Humans,
pubmed-meshheading:15921393-Immunocompromised Host,
pubmed-meshheading:15921393-Infection,
pubmed-meshheading:15921393-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:15921393-Lymphoma, Non-Hodgkin,
pubmed-meshheading:15921393-Male,
pubmed-meshheading:15921393-Middle Aged,
pubmed-meshheading:15921393-Pneumonia, Pneumocystis,
pubmed-meshheading:15921393-Risk,
pubmed-meshheading:15921393-Vidarabine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
|
|
pubmed:publicationType |
Letter,
Comparative Study,
Research Support, Non-U.S. Gov't
|
